<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03711253</url>
  </required_header>
  <id_info>
    <org_study_id>APP-18-01821</org_study_id>
    <nct_id>NCT03711253</nct_id>
  </id_info>
  <brief_title>Empiric Treatment for Acute HIV in the ED</brief_title>
  <acronym>EMTreatED</acronym>
  <official_title>Empiric Treatment for Suspected Acute HIV Infection in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An acceptance and feasibility study for immediate ART initiation and storage of laboratory
      specimens for individuals with suspected acute HIV infection who are diagnosed in one of the
      7 participating emergency rooms
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with suspected acute HIV infection willing to start immediate ART treatment will
      be given the ART regimen (bictegravir 50mg + tenofovir alafenamide 25 mg + emtricitabine 200
      mg fixed dose combination) on the day of diagnosis. Those patients beginning immediate ART in
      the ED who are willing to have additional laboratory specimens drawn in the ED and become
      part of a cohort to receive ART and have ongoing biological specimens obtained and will be
      followed for 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptance of immediate ART initiation</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of participants that initiate immediate ART and collection of laboratory specimens at baseline for suspected acute HIV</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact on linkage and engagement in care</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion with immediate ART for individuals with suspected acute HIV infection with linkage and 48 week engagement in care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART effects on cell associated HIV DNA</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in cell associated HIV DNA (assays TBD based on best practices at the time of study completion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART effects leukocytes</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in proportion of activated lymphocytes activated monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART effects inflammation</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes C-reactive protein levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART effects monocyte activation</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in soluble cd14 levels</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute HIV Infection</condition>
  <arm_group>
    <arm_group_label>Biktarvy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants get Biktarvy Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg in this single arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg</intervention_name>
    <description>antiretroviral therapy</description>
    <arm_group_label>Biktarvy</arm_group_label>
    <other_name>Biktarvy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected acute HIV infection

          -  agree to start immediate ART and to storage of laboratory specimens

        Exclusion Criteria:

          -  Known chronic HIV infection

          -  severe renal or liver disease

          -  drug allergy/hypersensitivity

          -  prohibited medications

          -  pregnancy

          -  co-morbidity that the investigator feels would compromise safety, data interpretation,
             or achieving study objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Jacobson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esther Lim, MPH</last_name>
    <phone>(323) 865-1645</phone>
    <phone_ext>6268909029</phone_ext>
    <email>Esther.Lim@med.usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Dube, MD</last_name>
    <phone>323.409.8288</phone>
    <email>mdube@usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LA County-USC Medical Center Emergency Department</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Menchine, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rand Schrader Health and Research Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Dube, MD</last_name>
      <phone>323-409-8285</phone>
      <email>mdube@usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Luis Mendez, BA</last_name>
      <phone>323.409.8283</phone>
      <email>lmendez@usc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Michael Dube</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>acute hiv infection</keyword>
  <keyword>emergency department</keyword>
  <keyword>antiretroviral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

